Precision Epigenomics Inc was selected to present their findings regarding the development of a liquid biopsy assay for non-small cell lung to the leadership and faculty of the University of Arizona.
Recent Posts
- EPISEEK Cancer Test: Could a Simple Blood Draw Catch Cancer Early?
- Precision Epigenomics Recognized at the 2026 AZBio Awards for Advancing Multi-Cancer Early Detection
- Precision Epigenomics Announces Unprecedented Early-Stage Sensitivity Data for EPISEEK® Multi-Cancer Early Detection Test
- Industry Excitement: GenomeWeb Survey Confirms High Interest in MCED Tests
- Precision Epigenomics and Front Line Mobile Health to Deliver EPISEEK Cancer Testing to First Responders in TX, CO, & GA
Recent Comments
No comments to show.
